LILRA2 selectively modulates LPS-mediated cytokine production and inhibits phagocytosis by monocytes.
AuthorsLu HK, Mitchell A, Endoh Y, Hampartzoumian T, Huynh O, Borges L, Geczy C, Bryant K, Tedla N
JournalPLoS One
PubMed ID22479404
'The activating immunoglobulin-like receptor, subfamily A, member 2 (LILRA2) is primarily expressed on the surface of cells of the innate immunity including monocytes, macrophages, neutrophils, basophils and eosinophils but not on lymphocytes and NK cells. LILRA2 cross-linking on monocytes induces pro-inflammatory cytokines while inhibiting dendritic cell differentiation and antigen presentation. ... More
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.
AuthorsOpalinski L, Szymczyk J, Szczepara M, Kucinska M, Krowarsch D, Zakrzewska M, Otlewski J
JournalInt J Mol Sci
PubMed ID29748524
Fibroblast growth factor receptor 1 (FGFR1) is a plasma membrane protein that transmits signals from the extracellular environment, regulating cell homeostasis and function. Dysregulation of FGFR1 leads to the development of human cancers and noncancerous diseases. Numerous tumors overproduce FGFR1, making this receptor a perspective target for cancer therapies. Antibody-drug ... More
Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
AuthorsWang Y, Fan S, Xiao D, Xie F, Li W, Zhong W, Zhou X,
JournalCancers (Basel)
PubMed ID31288450
Antibody-drug conjugate (ADC) is a novel efficient drug delivery system that has been successfully used in clinical practice, and it has become a research hotspot in the anti-tumor drug field. Acid-cleavable linkers were first used in clinical ADCs, but their structural variety (e.g., hydrazone and carbonate) is still limited, and ... More